Cancer-Associated VTE is a common and life-threatening condition in patients with cancer. The presence of cancer increases the risk of VTE, which is a major cause of death in these patients, second only to cancer itself.
Studies show that the occurence of VTE can increase the mortality of patients by 2- to 6-fold.
Furthermore, patients with cancer who develop VTE have a higher mortality rate and morbidity compared to those without cancer. VTE can also complicate cancer treatment and surgeries, particularly since it is the most common cause of death within 30 days of surgery. Understanding and managing the risk for cancer-associated VTE is crucial to preventing potential fatal outcomes.
This guideline focuses on the diagnosis, prevention, and treatment of cancer-associated venous thromboembolic disease (VTE), which includes deep vein thrombosis (DVT), pulmonary embolism (PE), superficial vein thrombosis (SVT), and splanchnic vein thrombosis (SPVT).